click below
click below
Normal Size Small Size show me how
Pharm Lecture 3
Question | Answer |
---|---|
NSAIDs examples | ibuprofen, indomethacin, diclofenac, celexocib, etoricoxib |
NSAIDs adverse effects | GI upsets, renal toxicity, cardiovascular events (COX-2 specific inhibitors) |
Ibuprofen adverse effects | few adverse effects |
Indomethacin adverse effects | GI upset and impaired renal function due to higher COX-1 selectivity |
Diclofenac adverse effects | GI upset and headaches (more potent than indomethacin) |
COX-2 inhibitors adverse effects | no GI upsets, heart attack and stroke |
NSAIDs mechanism | inhibit COX enzyme |
NSAIDs effects | antiinflammatory, analgesic, anti-pyretic |
COX pathway | Phospholipid --> (phospholipase A2) arachidonic acid --> (COX) PGG2 --> PGH2 --> PGE2, PGF2, PGI2, PGD2, TXA2 |
NSAID uses | treatment of acute or chronic conditions where pain and inflammation e.g. rheumatoid arthritis, limited effects on RA disease progression, used as bridge therapy |
Rheumatoid arthritis drug classes | NSAIDs, glucocorticoids, DMARDs, immunosuppressants, biological agents |
Glucocorticoid examples | prednisone |
Glucocorticoid adverse effects | immunosuppresion, hyperglycaemia, muscle breakdown, osteoporosis, adrenal insufficiency (HPA axis suppression), poor wound healing, thinning of skin, fat redistribution |
Prednisone adverse effects | hyperglycaemia, insomnia, euphoria, cushing's syndrome, truncal weight gain, osteoporsis, glaucoma, type II diabetes |
Glucocoritcoid mechanism | increased synthesis of lipocortin-1 --> inhibits PLA2, down-regulation of pro-inflammatory cytokines, up-regulation of anti-infalmmatory cytokines |
Glucocorticoid effects | anti-inflammatory and immunosuppressive, metabolic effects |
Glucocorticoid uses | limited effects on RA disease progression, used as bridge therapy |
DMARDs examples | methotrexate, gold salts, D-penicillamine, hydroxychloroquine, sulfasalazine, (cyclosporin A, azathioprine, leflunomide, infliximab, etanercept, rituximab) |
Methotrexate characteristics | first choice DMARD, low cost, effective, quicker onset |
Methotrexate adverse effects | mucosal ulceration, hepatic and renal toxicity, skin reactions, nausea, teratogenic |
Methotrexate mechanism | inhibits metabolism of folic acid --> inhibits thymidine synthesis --> inhibits cell growth of pannus tissue |
Gold salts mechanism | inhibits IL-1 and TNF-alpha production, inhibits mitogen-induced lymphocyte proflieration, inhibits neutrophil chemotaxis and free radical production |
Gold salts adverse effects | decreased appetite, itchy skin, mouth sores, nausea, hair thinning, diarrhoea, thrombocytopenia |
D-penicillamine mechanism | metal chelator, reduces number of T-lymphocytes, inhibits macrophage function, decrease IL-1 and rheumatoid factor, pevents collagen cross-linking |
D-penicillamine adverse effects | hepatic and renal dysfunction, rash, nausea, vomiting |
Hydroxychloroquine adverse effects | rash, GI upset, headaches |
Hydroxychloroquine characteristics | 50% patients respond, low toxicity |
Sulfasalazine adverse effects | skin reactions, GI disturbances, headaches, nausea |
Sulfasalazine mechanism | may treat unrecognised UC --> reduces arthritis symptoms |
Cyclosporin A adverse effects | renal and hepatic toxicity |
Cyclosporin A mechanism | inhibits calicneurim --> inhibits IL-2 synthesis and activation |
Cyclopsorin A characteristics | most effective when combined with DMARDs --> decreased dose |
Azathioprine adverse effects | skin eruptions, nausea, suppress bone marrow --> thrombocytopenia, leukopenia |
Azathioprine mechanism | purine analog |
Leflunomide adverse effects | hepatic toxicity, diarrhoea, rash, teratogenic |
Leflunomide mechanism | inhibits enzyme involved in pyrimidine synthesis |
Infliximab mechanism | TNF-alpha inhibitor (monoclonal antibody) |
Etanercept mechanism | TNF-alpha receptor fusion protein |
Biological agents administration | only IV infusion or subcutaneous injection |
TNF-alpha inhibitors adverse effects | infusion-related reaction, blood dyscrasias, infections |
Anakinra mechanism | IL-1 receptor antagonist analog |
Abatacept mechanism | blocks co-stimulatory signal between APC and T cell |
Rituximab mechanism | depletes B cells |